Table of Contents

• Overview of (N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE in Clinical Research
• Phase 2 Clinical Trial Design and Objectives
• Alzheimer’s Disease as the Target Condition
• PET Imaging Approach and Multiple Tracers
• Study Endpoints and Measurements
• Participant Enrollment and Study Population

Overview of (N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE in Clinical Research

(N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE, also referred to as [11C]-UCB-J, is a radioactive tracer being investigated in clinical trials for its ability to measure synaptic density in the human brain^[1]. This substance represents a recent advancement in PET radioligand technology, offering researchers a tool to visualize and quantify the connections between brain cells in living patients^[1].

The clinical investigation of (N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE focuses specifically on understanding disease processes in Alzheimer’s disease^[1]. Unlike traditional medications that treat symptoms or slow disease progression, this tracer serves as a diagnostic and research tool, allowing scientists to observe what happens inside the brain as the disease develops.

The current research program examining (N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE aims to analyze the complex relationships between different pathological processes in Alzheimer’s disease^[1]. By measuring synaptic density alongside other disease markers, researchers hope to gain insights into how brain cell connections are lost during disease progression.

Phase 2 Clinical Trial Design and Objectives

The clinical trial investigating (N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE is classified as a Phase 2 study, identified by the trial number NCT05911178^[1]. Phase 2 trials represent an important stage in clinical research where investigators evaluate the effectiveness of a diagnostic tool or treatment approach and gather more detailed information about its optimal use.

This trial is designed as an interventional study, meaning that participants will undergo specific procedures according to a structured research protocol^[1]. The interventional nature allows researchers to actively measure and analyze the effects of using (N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE in combination with other imaging tracers.

The primary objective of this Phase 2 trial is to analyze the interplay between microglial activation and tau pathology in Alzheimer’s disease patients, and to determine how these processes affect synaptic density^[1]. This multi-faceted approach requires the use of three different PET tracers to capture different aspects of the disease simultaneously.

The study has received authorization status, indicating that regulatory authorities have approved the research protocol and the trial can proceed with participant recruitment and data collection^[1]. This authorization reflects careful review of the study design, safety measures, and scientific merit.

Alzheimer’s Disease as the Target Condition

The clinical trial focuses exclusively on Alzheimer’s disease, a progressive neurodegenerative disorder that affects millions of people worldwide^[1]. Alzheimer’s disease is characterized by the gradual loss of memory and cognitive function, ultimately affecting a person’s ability to perform daily activities.

The research specifically examines three critical aspects of Alzheimer’s disease pathology:

• Microglial activation: This represents the brain’s inflammatory response, where immune cells called microglia become activated in response to disease processes^[1]. While microglia normally protect the brain, their activation in Alzheimer’s disease can contribute to further damage.
• Tau pathology: The abnormal accumulation of tau protein forms tangles inside brain cells, which is one of the hallmark features of Alzheimer’s disease^[1]. These tangles interfere with normal cell function and contribute to cell death.
• Synaptic density loss: The reduction in connections between brain cells is closely linked to cognitive decline in Alzheimer’s disease^[1]. Measuring this loss provides important information about disease severity and progression.

Understanding how these three pathological processes interact is crucial for developing better treatments for Alzheimer’s disease. The trial aims to determine whether microglial activation and tau pathology directly influence the loss of synaptic connections, which could help identify new therapeutic targets.

PET Imaging Approach and Multiple Tracers

The clinical trial employs Position Emission Tomography (PET) imaging, a sophisticated medical imaging technique that allows researchers to visualize biological processes inside the living brain^[1]. PET imaging works by detecting radiation emitted by radioactive tracers that have been introduced into the body.

The study protocol includes three different PET tracers, each designed to measure a specific aspect of Alzheimer’s disease pathology:

• [18F]-DPA-714: This tracer is used to measure microglial activation in the brain^[1]. By binding to activated microglia, it allows researchers to see where inflammation is occurring and how severe it is.
• [18F]-Ro948: This radioligand specifically binds to tau protein tangles, enabling visualization and quantification of tau pathology throughout the brain^[1]. This helps researchers understand the distribution and severity of tau accumulation.
• (N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE) or [11C]-UCB-J: This is the primary tracer being investigated in this trial, designed to measure synaptic density^[1]. It provides information about the number and health of connections between brain cells.

The use of multiple tracers in the same study population allows researchers to perform in vivo analysis, meaning they can observe these processes in living patients rather than only in laboratory samples or post-mortem tissue^[1]. This approach provides more accurate and clinically relevant information about how Alzheimer’s disease progresses.

The combination of these three imaging tracers enables researchers to examine correlations between inflammation, protein pathology, and synaptic loss, potentially revealing cause-and-effect relationships that could inform future treatment development.

Study Endpoints and Measurements

The trial titled “Impact of microglial activation on synaptic density in Alzheimer’s disease” clearly defines its research focus through its name and objectives^[1]. The study aims to determine how microglial activation impacts the density of synapses in patients with Alzheimer’s disease.

The primary measurements in this trial include:

• Quantification of synaptic density: Using (N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE, researchers will measure the concentration of synapses in different brain regions^[1]. This provides a direct measure of brain cell connectivity.
• Assessment of microglial activation levels: The [18F]-DPA-714 tracer will quantify the extent and location of microglial activation throughout the brain^[1]. This helps identify areas of active inflammation.
• Evaluation of tau pathology distribution: The [18F]-Ro948 tracer will map where tau tangles are located and how severe the pathology is in different brain regions^[1].

By analyzing the relationships between these three measurements, researchers can determine whether there are correlations or causal relationships between inflammation, tau accumulation, and synaptic loss. This information is crucial for understanding the sequence of events in Alzheimer’s disease progression and identifying which processes might be the best targets for therapeutic intervention.

Participant Enrollment and Study Population

The Phase 2 clinical trial plans to enroll a total of 90 participants^[1]. This sample size is designed to provide sufficient statistical power to detect meaningful relationships between microglial activation, tau pathology, and synaptic density while accounting for individual variation among patients.

The study population consists of individuals with Alzheimer’s disease who will undergo PET imaging with all three radioactive tracers^[1]. The enrollment of 90 participants represents a substantial cohort for a neuroimaging study, allowing for robust analysis of the complex relationships between different disease markers.

As an interventional study, participants will be asked to undergo specific imaging procedures as part of the research protocol^[1]. This typically involves multiple PET scanning sessions to acquire images with each of the three different tracers.

The trial’s authorized status indicates that participant recruitment can proceed according to the approved protocol^[1]. Potential participants would need to meet specific eligibility criteria related to their Alzheimer’s disease diagnosis and overall health status to ensure the safety and scientific validity of the research.